Date | Title | Description | |
---|---|---|---|
10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
01 Aug 2024 | Other relevant information | The Company has agreed to execute the share capital reduction approved by the 2024 Ordinary General Meeting to amortize treasury shares, among which those acquired in the framework of the own shares repurchase program. | Download |
31 Jul 2024 | Liquidity and counterparty agreements | Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. | Download |
08 Jul 2024 | Other relevant information | The Company informs about the dividends payment. | Download |
04 Jul 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2024 | Download |
24 Jun 2024 | Announcement of General Shareholders' Meeting | The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |